Hybio Pharmaceutical (300199.SZ): Preclinical studies of HY3003 tablets show better weight loss effects than semaglutide

Zhitong Finance APP News, Hybio Pharmaceutical (300199.SZ) announced that the company recently completed a preclinical pharmacodynamic comparative study of HY3003 tablets for the weight-loss indication. The study results showed that HY3003 tablets demonstrated good weight-loss effects in both DIO mouse and DIO rat obesity models, and under the same experimental conditions, the weight-loss effect was superior to that of the marketed semaglutide tablets, indicating good development prospects for this product.